On June 30, Xunce (03317.HK) fell 5.28% in regular trading, trading at 102.6 HKD/share, with turnover of approximately 95.17 million HKD.

On the news front, the stock surged over 26% in the previous session driven by multiple top-tier investment banks initiating coverage with buy ratings and shareholder approval of a share buyback authorization. However, approximately 6.41 million shares held by IPO cornerstone investors were officially unlocked on June 29, with actual selling pressure concentrating on today's session. After the sharp single-day rebound from deeply oversold levels — the stock had retreated over 70% from its peak of 382.8 HKD — profit-taking momentum intensified, weighing on the share price.

Additionally, the company announced a cooperation framework agreement with Beijing International Big Data Exchange (BJIDEX) on June 29, focusing on building standardized pharmaceutical industry databases and data governance compliance initiatives.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)